Talecris: Buyout won't hamper Clayton expansion
Talecris Therapeutics expects to move ahead with its $270 million expansion plan at the huge Clayton blood plasma plant even though the RTP-based firm is being sold.Posted — Updated
Talecris Therapeutics (Nasdaq: TLRS) expects to move ahead with its $270 million expansion plan at the huge Clayton blood plasma plant even though the RTP-based firm is being sold.
Talecris officials said Monday that they “fully expect” the plant program and the related addition of 259 jobs to proceed as announced last fall.
Early Monday, Talecris and Spain-based Grifols announced their boards had agreed to a $4 billion buyout of Talecris.
“This transaction is about growth and creating a global platform,” Talecris said in an e-mail response to an inquiry from LTW and WRAL.com.
“While the deal has just been announced, Grifols is interested in Talecris' manufacturing capabilities in order to produce a more balanced and broad portfolio of plasma protein therapies,” Talecris added.
“As such, we fully expect that they will continue with the new fractionation build-out in Clayton.
Grifols said in its announcement of the Talecris deal that it is expected to generate approximately $230 million in operating synergies. Grifols specializes in the pharmaceutical-hospital sector and has operations in more than 90 countries.
Last November, Talecris announced plans to add 259 jobs and invest nearly $270 million over the next seven years to expand its blood plasma therapeutics plant in Clayton.
The North Carolina Economic Investment Committee agreed to a contract that will award payroll tax rebates up to $3.66 million over 12 years if new job targets are met and sustained through the Job development Investment Grant program.
Talecris also was awarded a $250,000 grant from the state’s One North Carolina fund.